Bright Minds Biosciences (DRUG) Accumulated Expenses (2024 - 2025)
For the quarter ending Q3 2025, Accumulated Expenses rose 1183.36% year-over-year to $392781.8, compared with a TTM value of $392781.8 through Sep 2025, up 1183.36%, and an annual FY2025 reading of $392781.8, up 1183.36% over the prior year.
Bright Minds Biosciences (DRUG) has disclosed Accumulated Expenses for 2 consecutive years, with $392781.8 as the latest value for Q3 2025.
- Accumulated Expenses reached $392781.8 in Q3 2025 per DRUG's latest filing, up from $30605.7 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $392781.8 in Q3 2025 and bottomed at $30605.7 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Bright Minds Biosciences | 464.72 Mn | 405.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 392,781.82 |
| Sep 30, 2024 | 30,605.71 |